The genomic landscape of response to EGFR blockade in colorectal cancer
Open accessThe DOI matches its Crossref record; 41 of the 41 references it cites were found in a registry or an index.
Abstract
Colorectal cancer is the third most common cancer worldwide, with 1.2 million patients diagnosed annually. In late-stage colorectal cancer, the most commonly used targeted therapies are the monoclonal antibodies cetuximab and panitumumab, which prevent epidermal growth factor receptor (EGFR) activation. Recent studies have identified alterations in KRAS and other genes as likely mechanisms of primary and secondary resistance to anti-EGFR antibody therapy. Despite these efforts, additional mechanisms of resistance to EGFR blockade are thought to be present in colorectal cancer and little is known about determinants of sensitivity to this therapy. To examine the effect of somatic genetic changes in colorectal cancer on response to anti-EGFR antibody therapy, here we perform complete exome sequence and copy number analyses of 129 patient-derived tumour grafts and targeted genomic analyses of 55 patient tumours, all of which were KRAS wild-type. We analysed the response of tumours to anti-EGFR antibody blockade in tumour graft models and in clinical settings and functionally linked therapeutic responses to mutational data. In addition to previously identified genes, we detected mutations in ERBB2, EGFR, FGFR1, PDGFRA, and MAP2K1 as potential mechanisms of primary resistance to this therapy. Novel alterations in the ectodomain of EGFR were identified in patients with acquired resistance to EGFR blockade. Amplifications and sequence changes in the tyrosine kinase receptor adaptor gene IRS2 were identified in tumours with increased sensitivity to anti-EGFR therapy. Therapeutic resistance to EGFR blockade could be overcome in tumour graft models through combinatorial therapies targeting actionable genes. These analyses provide a systematic approach to evaluating response to targeted therapies in human cancer, highlight new mechanisms of responsiveness to anti-EGFR therapies, and delineate new avenues for intervention in managing colorectal cancer.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“EGFR somatic sequence changes, including G465R, G465E, S468R and S492R, located at the extracellular domains (ECDs) of the EGFR-mAb interaction interface, confer resistance to cetuximab and panitumumab by preventing mAb binding [10, 67, 68].”
From Resistance to anti-EGFR therapies in metastatic colorectal cancer: underlying mechanisms and reversal strategies (2021) · cites this paper as [10]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“However, in late-line therapy, only 12–17% of patients have durable responses to anti-EGFR monotherapy [4]”
From Combined blockade of EGFR and glutamine metabolism in preclinical models of colorectal cancer (2020) · cites this paper as [4]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Gene mutations downstream of the EGFR signalling pathway, including RAS/RAF/MEK and PI3K/AKT/mTOR, significantly contribute to drug resistance [9–11].”
From Resistance to anti-EGFR therapies in metastatic colorectal cancer: underlying mechanisms and reversal strategies (2021) · cites this paper as [10]
The check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“This is supported by our observation, consolidated after monitoring hundreds of mCRC PDXs exposed to cetuximab (10, 25, 27, 29, 30), that complete responses are exceptional events.”
From Synthetic Lethal Interaction with BCL-XL Blockade Deepens Response to Cetuximab in Patient-Derived Models of Metastatic Colorectal Cancer (2023) · cites this paper as [29]
Experimental — accuracy not yet measuredIn the citing paper
“A growing number of studies suggest that mutations in the extracellular domain (ECD) of the EGFR, such as S492R, G465E, R451C and K467T, prevent binding cetuximab and make CRC resistant to anti-EGFR mAbs [141,142,143,144].”
From Drug Resistance in Colorectal Cancer: From Mechanism to Clinic (2022) · cites this paper as [144]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Needleman, S. B., & Wunsch, C. D. (1970) · Journal of Molecular Biology · doi:10.1016/0022-2836(70)90057-4 · Cited by 11,288 · cited 1×
“Sequence reads were aligned against the human reference genome (version hg18) using ELAND with additional realignment of select regions using the Needleman-Wunsch method 35 .”
Detection of Circulating Tumor DNA in Early- and Late-Stage Human Malignancies
Bettegowda, C., Sausen, M., Leary, R. J., Kinde, I., Wang, Y., Agrawal, N., Bartlett, B. R., Wang, H., Luber, B., Alani, R. M., et al. (2014) · Science Translational Medicine · doi:10.1126/scitranslmed.3007094 · Cited by 5,067
Self-citationWild-Type KRAS Is Required for Panitumumab Efficacy in Patients With Metastatic Colorectal Cancer
Amado, R. G., Wolf, M., Peeters, M., Van Cutsem, E., Siena, S., Freeman, D. J., Juan, T., Sikorski, R., Suggs, S., Radinsky, R., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.14.7116 · Cited by 3,207 · cited 1×
“A mutation in the tumour was identified as a candidate somatic mutation only when (1) distinct paired reads contained the mutation in the tumour, (2) the number of distinct paired reads containing a particular mutation in the tumour was at least 2% of the total distinct read pairs for targeted analyses and 10% of read…”
Self-citationThe Consensus Coding Sequences of Human Breast and Colorectal Cancers
Sjöblom, T., Jones, S., Wood, L. D., Parsons, D. W., Lin, J., Barber, T. D., Mandelker, D., Leary, R. J., Ptak, J., Silliman, N., et al. (2006) · Science · doi:10.1126/science.1133427 · Cited by 3,169
Self-citationPDGFRA Activating Mutations in Gastrointestinal Stromal Tumors
Heinrich, M. C., Corless, C. L., Duensing, A., McGreevey, L., Chen, C.-J., Joseph, N., Singer, S., Griffith, D. J., Haley, A., Town, A., et al. (2003) · Science · doi:10.1126/science.1079666 · Cited by 2,301
De Roock, W., Claes, B., Bernasconi, D., De Schutter, J., Biesmans, B., Fountzilas, G., Kalogeras, K. T., Kotoula, V., Papamichael, D., Laurent-Puig, P., et al. (2010) · The Lancet Oncology · doi:10.1016/s1470-2045(10)70130-3 · Cited by 2,144
Self-citationEmergence of KRAS mutations and acquired resistance to anti-EGFR therapy in colorectal cancer
Misale, S., Yaeger, R., Hobor, S., Scala, E., Janakiraman, M., Liska, D., Valtorta, E., Schiavo, R., Buscarino, M., Siravegna, G., et al. (2012) · Nature · doi:10.1038/nature11156 · Cited by 1,889 · cited 6×
“Common CRC driver genes were identified at expected frequencies in the tumours analysed (Supplementary Tables 3–5).”
InfluentialSelf-citationThe molecular evolution of acquired resistance to targeted EGFR blockade in colorectal cancers
Diaz Jr, L. A., Williams, R. T., Wu, J., Kinde, I., Hecht, J. R., Berlin, J., Allen, B., Bozic, I., Reiter, J. G., Nowak, M. A., et al. (2012) · Nature · doi:10.1038/nature11219 · Cited by 1,713
Coiffier, B., Osmanov, E. A., Hong, X., Scheliga, A. A. D. S., Mayer, J., Offner, F., Rule, S. A., Teixeira, A., Walewski, J. A., Vos, S., et al. (2011) · The Lancet Oncology · doi:10.1016/s1470-2045 · Cited by 1,631
Van Cutsem, E., Cervantes, A., Nordlinger, B., & Arnold, D. (2014) · Annals of Oncology · doi:10.1093/annonc/mdu260 · Cited by 1,167
Cited by
Items 401–478 of 478
Molecular testing panel in colorectal cancer
Ding, Y., & Chen, G. (2022) · Human Pathology Reports · doi:10.1016/j.hpr.2022.300632 · Cited by 1
Zaboli, E., MajiMiriha, D. S., Naghshvar, F., Alizadeh‐Navaei, R., & HajiMiriha, M. S. (2023) · Tabari Biomedical Student Research Journal · doi:10.32598/tbsrj.v5i2.10530 · Cited by 1
Systems Biology Approaches for Cancer Biology
Dutta, B., Lahiri, D., Nag, M., Sarkar, N., Ray, R. R., & Bhattacharya, D. (2024) · Springer eBooks · doi:10.1007/978-981-99-9462-5_21 · Cited by 1
Ren, R., Zhang, J., He, Y., Zeng, X., Zhou, Y., Shen, L., Li, Y., Li, D., & Zhao, H. (2024) · MedComm – Oncology · doi:10.1002/mog2.70002 · Cited by 1
A pan-cancer, pan-treatment model for predicting drug responses from patient-derived xenografts
Gupta, S., Mohani, V. K., Ghislat, G., Ballester, P. J., & Ahmad, S. (2025) · NAR Genomics and Bioinformatics · doi:10.1093/nargab/lqaf111 · Cited by 1
“PDXs maintain the genetic and epigenetic mutations and other features that contribute to drug resistance, and their response to drugs is correlated with those observed in the clinic [ 20–25 ].”
Bioinformatical analysis of gene expressions and pathways in human colorectal cancer tissues
Chiba, M. (2019) · Biomedical Research · doi:10.35841/biomedicalresearch.30-19-022 · Cited by 1
“Using one of these pathways, the relationship among TGF-β, PI3K-Akt, and vascular endothelial growth factor (VEGF)-A-VEGF receptor 2 (VEGFR2) signaling pathways was predicted.”
BackgroundInfluentialMignone, A., Grand, A., Fiori, A., Médico, E., & Bertotti, A. (2019) · Database · doi:10.1093/database/baz080 · Cited by 1
Self-citationMOLECULAR FEATURES AND MOUSE MODELS OF COLORECTAL CANCER.
Fearon, E. R. (2018) · Europe PMC (PubMed Central) · Cited by 1
Colorectal Cancer Genetics: An Overview of the Actionable Building Blocks
Bairi, K. E., Lengyel, C. G., Marra, A., & Afqir, S. (2020) · Springer eBooks · doi:10.1007/978-3-030-53821-7_2 · Cited by 1
Zhu, N. W., Fang, X., Li, D., Yang, M., Zhu, L., Zhong, L., Weng, S., Wang, J., & Yuan, Y. (2021) · PubMed Central · Cited by 2
Taniguchi, F., Nyuya, A., Toshima, T., Yasui, K., Mori, Y., Okawaki, M., Kishimoto, H., Umeda, Y., Fujiwara, T., Tanioka, H., et al. (2021) · Future Science OA · doi:10.2144/fsoa-2021-0059 · Cited by 2
Ly, S. H. (2018) · Digital Access to Scholarship at Harvard (DASH) (Harvard University) · Cited by 2
Graham, T. A. (2021) · Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature · doi:10.3410/f.736145192.793584899 · Cited by 1
Davies, E. B. J., Meyer, J., Basiliya, K., Corbett, G. D., Bowden, D. J., Chan, D. K. H., O'Cathail, S. M., Krakowska, M., Jabbar, F., & Church, D. N. (2024) · Wiley eBooks · doi:10.1002/9781119756422.ch12 · Cited by 1
µ Seq: Universal mutation rate quantification via deep sequencing of a single clonal expansionPreprint
Pompei, S., Geroldi, A., Rivetti, P., Grassi, E., Vurchio, V., Tallarico, G., Corti, G., Tattini, L., Liti, G., Bertotti, A., et al. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2025.04.17.649315 · Cited by 1
Self-citationRAS and RAF mutation status in the selection of patients for anti-EGFR therapy
Mulet-Margalef, N., Doménech, M., & Salazar, R. (2016) · Colorectal Cancer · doi:10.2217/crc-2015-0013
Antibodies for Treatment of Metastatic Colorectal Cancer
Heinemann, V., & Stintzing, S. (2017) · Springer eBooks · doi:10.1007/978-3-319-43063-8_9
SURGICAL PATHOLOGY AND MOLECULAR DIAGNOSTICS: A CRITICAL VIEW
Ivantsov, A. O. (2018) · Practical oncology · doi:10.31917/1903236
Advances in personalized gastroenterology and hepatology 2016
Hubert, E. B. (2016) · Russian Journal of Gastroenterology Hepatology Coloproctology · doi:10.22416/1382-4376-2016-26-3-4-10
Gillis, N. (2017) · Carolina Digital Repository (University of North Carolina at Chapel Hill) · doi:10.17615/3ttj-j094
Salem, M. E., Weinberg, B. A., Khalek, F. J. A., Desai, J. R., Warner, E. A., Hartley, M. L., & Marshall, J. L. (2019) · Springer eBooks · doi:10.1007/978-3-030-18890-0_8
Vakiani, E. (2019) · Springer eBooks · doi:10.1007/978-3-030-22922-1_7
Precision Medicine in Metastatic Colorectal Cancer—Finding and Hitting the Right Targets
Ciombor, K. K., & Bekaii‐Saab, T. (2020) · touchREVIEWS in Oncology & Haematology · doi:10.17925/ohr.2020.16.1.36
Nikolodimou, V., & Agapow, P. (2020) · medRxiv · doi:10.1101/2020.11.21.20232041 · Cited by 2
“…on mCRC patients provides clear evidence on response favouring KRAS exon 2 wild-type status [41, 42], however, further investigation of tumour mutational data detected mutations in KRAS, EGFR and several other genes as potential mechanisms of primary resistance to an antiEGFR mAb therapy [43, 44].”
BackgroundGLUD1 Promotes Cetuximab Resistance in Metastasis Colorectal CancerPreprint
Peng, K., Xu, X., Liu, M., Liang, L., Yuan, Y., Hou, Y., Yu, Y., & Liu, T. (2021) · SSRN Electronic Journal · doi:10.2139/ssrn.3907832
Molecular and immune landscape of colorectal liver metastases
Dagenborg, V. J. (2021) · NORA - Norwegian Open Research Archives
Murray, E. M. (2020) · Open Scholarship Institutional Repository (Washington University in St. Louis) · doi:10.7936/xjje-vr62
Macgregor‐Das, A. M., & Goggins, M. (2017) · Springer eBooks · doi:10.1007/978-1-4939-6631-8_56-1
Taniguchi, F., Nyuya, A., Toshima, T., Yasui, K., Mori, Y., Okawaki, M., Kishimoto, H., Umeda, Y., Fujiwara, T., Tanioka, H., et al. (2020) · Research Square · doi:10.21203/rs.3.rs-91128/v1
Prädiktive Testung von Tumorgewebe und ihre klinischen Konsequenzen
Hoffmann, J. (2022) · Springer Reference Medizin · doi:10.1007/978-3-662-46764-0_148-1
Wagman, L. D., Geller, D. A., Jacobs, S. A., Petrelli, N. J., Allegra, C. J., Lipchik, C., Pogue–Geile, K. L., Srinivasan, A., Wang, Y., O’Connell, M. J., et al. (2022) · Journal of Surgical Oncology · doi:10.1002/jso.27078
“Mechanisms leading to such resistance to targeted anti‐EGFR therapy have been alluded to above.(31) The RPPA results are consistent with the high failure rates post‐resection, suggesting that micrometastatic disease was resistant to FOLFOX plus cetuximab either through pre‐existing or by acquired mechanisms.”
ResultNanoencapsulation of tyrosine kinase inhibitors for oncological therapeutics
Nguyen, H. L., Gupta, R. K., & Nguyen, T. A. (2022) · Elsevier eBooks · doi:10.1016/b978-0-323-91229-7.00014-3 · Cited by 1
Leto, S. M., Ferri, M., Sassi, F. P., Zanella, E. R., Cottino, F., Vurchio, V., Catalano, I., Ferrero, A., Zingaretti, C. C., Marchiò, C., et al. (2023) · doi:10.1158/1078-0432.c.6533128.v1
Self-citationJacobs, S. A., Lee, J. J., George, T. J., Wade, J. L., Stella, P. J., Wang, D., Sama, A. R., Piette, F., Pogue–Geile, K. L., Kim, R. S., et al. (2023) · doi:10.1158/1078-0432.c.6530607.v1
Sun, L., Wu, Q., Huan, X., Tian, C.-Q., Wang, Y.-Q., & Miao, Z. (2023) · doi:10.1158/1541-7786.c.6545633.v1
Bagchi, A., Haidar, J. N. S., Eastman, S. W., Vieth, M., Topper, M. J., Iacolina, M. D., Walker, J. M., Forest, A., Shen, Y., Novosiadly, R. D., et al. (2023) · doi:10.1158/1535-7163.22510134
Vangala, D., Ladigan, S., Liffers, S. T., Noseir, S., Maghnouj, A., Götze, T.-M., Verdoodt, B., Klein‐Scory, S., Godfrey, L., Zowada, M. K., et al. (2021) · Figshare · doi:10.6084/m9.figshare.14998919
Vangala, D., Ladigan, S., Liffers, S. T., Noseir, S., Maghnouj, A., Götze, T.-M., Verdoodt, B., Klein‐Scory, S., Godfrey, L., Zowada, M. K., et al. (2021) · Figshare · doi:10.6084/m9.figshare.14998901
Vangala, D., Ladigan, S., Liffers, S. T., Noseir, S., Maghnouj, A., Götze, T.-M., Verdoodt, B., Klein‐Scory, S., Godfrey, L., Zowada, M. K., et al. (2021) · Figshare · doi:10.6084/m9.figshare.14998910
Vangala, D., Ladigan, S., Liffers, S. T., Noseir, S., Maghnouj, A., Götze, T.-M., Verdoodt, B., Klein‐Scory, S., Godfrey, L., Zowada, M. K., et al. (2021) · Figshare · doi:10.6084/m9.figshare.14998925
Vangala, D., Ladigan, S., Liffers, S. T., Noseir, S., Maghnouj, A., Götze, T.-M., Verdoodt, B., Klein‐Scory, S., Godfrey, L., Zowada, M. K., et al. (2021) · Figshare · doi:10.6084/m9.figshare.14998916
Vangala, D., Ladigan, S., Liffers, S. T., Noseir, S., Maghnouj, A., Götze, T.-M., Verdoodt, B., Klein‐Scory, S., Godfrey, L., Zowada, M. K., et al. (2021) · Figshare · doi:10.6084/m9.figshare.14998913
Reply to A. Sartore-Bianchi et al
Battaglin, F., Ou, F., Innocenti, F., & Lenz, H. (2024) · Journal of Clinical Oncology · doi:10.1200/jco.24.01086
Unraveling the mystery of treatment resistance in colorectal cancer
Dlamini, Z., Hull, R., & Kaufmann, A. M. (2024) · Elsevier eBooks · doi:10.1016/b978-0-443-33475-7.00009-3
Marinello, A., & Aldea, M. D. (2024) · Elsevier eBooks · doi:10.1016/b978-0-323-98808-7.00004-7 · Cited by 1
Clinical Characteristics of and Treatment Pattern for EGFR-Amplified Colorectal Cancer
Kim, S.-E., Jeong, H., Kim, J. E., Kim, D., Hong, Y. S., Kim, D., Kim, T., Lee, J. S., & Kim, T. W. (2025) · Cancer Research and Treatment · doi:10.4143/crt.2024.569
“…that patients with EGFR amplification have a higher enrichment in other genetic mutations compared with those without amplification, suggesting a greater likelihood of developing resistance to conventional treatments by activating various signaling pathways from co-occurring mutations [1,7,8].”
Remarkable Response on Cetuximab in Non-V600e Braf Mutated Colon Cancer: A Case ReportPreprint
Wu, X., Xiao, Y., Jian-yue, L., Ji, Y., Li, L., Nie, M., Hu, Y., Huo, J., & Wei, G. (2025) · SSRN Electronic Journal · doi:10.2139/ssrn.5173691
King, G. T., Baker, K. K., Coveler, A. L., Harris, W. P., Cohen, S. A., Shankaran, V., Zhen, D. B., Safyan, R. A., Lee, H. H., Alidina, A., et al. (2025) · Cancers · doi:10.3390/cancers17111830
“For example, a patient with KRAS MUT FGFR1 -amplified BTC had durable stable disease, PFS of 8 months, and OS of 22.8 months, despite the known association of activated FGFR1 signaling with resistance to EGFR-targeted therapies [39].”
InfluentialTang, W., Zheng, H., Wang, Q., Zhang, X., Zhou, S., Ge, C., & Fu, J. (2025) · Case Reports in Oncology · doi:10.1159/000549570
“Activation of the HER2 signaling pathway can circumvent EGFR inhibition by engaging downstream signaling bypass pathways (such as the PI3K-AKT-mTOR and MAPK pathways) [20].”
Sato, T., Nagashima, F., Okano, N., Nishioka, M., Hayashi, M., Saito, Y., Hisamatsu, T., & Hironaka, S. (2025) · International Cancer Conference Journal · doi:10.1007/s13691-025-00826-2
“predictive biomarkers for response [5–7].”
Liang, L., Liu, M., Sun, X., Yuan, Y., Peng, K., Rashid, K., Yu, Y., Yuehong, C., Chen, Y., & Liu, T. (2021) · Figshare · doi:10.6084/m9.figshare.14432207
Mazzeschi, M., Sgarzi, M., Romaniello, D., Gelfo, V., Cavallo, C., Ambrosi, F., Morselli, A., Miano, C., Laprovitera, N., Girone, C., et al. (2022) · Figshare · doi:10.6084/m9.figshare.19451499
Geng, Y., Zheng, X., Zhang, D., Wei, S., Feng, J., Wang, W., Zhang, L., Wu, C., & Hu, W. (2024) · Figshare · doi:10.6084/m9.figshare.26716978
Geng, Y., Zheng, X., Zhang, D., Wei, S., Feng, J., Wang, W., Zhang, L., Wu, C., & Hu, W. (2024) · Figshare · doi:10.6084/m9.figshare.26716990
Vangala, D., Ladigan, S., Liffers, S. T., Noseir, S., Maghnouj, A., Götze, T.-M., Verdoodt, B., Klein‐Scory, S., Godfrey, L., Zowada, M. K., et al. (2021) · Figshare · doi:10.6084/m9.figshare.14998907
Liang, L., Liu, M., Sun, X., Yuan, Y., Peng, K., Rashid, K., Yu, Y., Yuehong, C., Chen, Y., & Liu, T. (2021) · Figshare · doi:10.6084/m9.figshare.14432198
Geng, Y., Zheng, X., Zhang, D., Wei, S., Feng, J., Wang, W., Zhang, L., Wu, C., & Hu, W. (2024) · Figshare · doi:10.6084/m9.figshare.26716993
Liang, L., Liu, M., Sun, X., Yuan, Y., Peng, K., Rashid, K., Yu, Y., Yuehong, C., Chen, Y., & Liu, T. (2021) · Figshare · doi:10.6084/m9.figshare.14432201
Geng, Y., Zheng, X., Zhang, D., Wei, S., Feng, J., Wang, W., Zhang, L., Wu, C., & Hu, W. (2024) · Figshare · doi:10.6084/m9.figshare.26716984
Geng, Y., Zheng, X., Zhang, D., Wei, S., Feng, J., Wang, W., Zhang, L., Wu, C., & Hu, W. (2024) · Figshare · doi:10.6084/m9.figshare.26716981
Geng, Y., Zheng, X., Zhang, D., Wei, S., Feng, J., Wang, W., Zhang, L., Wu, C., & Hu, W. (2024) · Figshare · doi:10.6084/m9.figshare.26716987
Liang, L., Liu, M., Sun, X., Yuan, Y., Peng, K., Rashid, K., Yu, Y., Yuehong, C., Chen, Y., & Liu, T. (2021) · Figshare · doi:10.6084/m9.figshare.14432204
叶, 唐. (2025) · Advances in Clinical Medicine · doi:10.12677/acm.2025.15123695
Actionable subgroups (II): HER2+, NTRK/RET/ALK and MSI-H/TMB high
Vivas, C. S., Pena, M. B., Gimeno, D. D., & Rodríguez, J. C. R. (2026) · Revisiones en cáncer · doi:10.20960/revcancer.00135
Falco, V. D., Vitiello, P. P., Ciardiello, D., Grasso, G., Mariella, E., Martini, G., Napolitano, S., Cardone, C., Arrichiello, G., Varriale, E., et al. (2026) · ESMO Gastrointestinal Oncology · doi:10.1016/j.esmogo.2026.100303
“18 Clinical experience with cabozantinib alone (AGICC 17CRC01 trial), 19 or in combination with immunotherapy (CAMILLA trial) 20 in pretreated mCRC also support its antitumor activity in this setting.”
Wen, J.-K., Xia, J., Yu, L., Xu, G.-L., Ye, G.-F., & Lin, Y.-H. (2026) · World Journal of Gastrointestinal Oncology · doi:10.4251/wjgo.v18.i4.114567 · Cited by 1
Özdemir, Ö., Günenç, D., Taşkaynatan, H., Peker, P., Kahraman, E. G., Biter, S., Paydaş, S., Önder, T., Ateş, Ö., Er, M. M., et al. (2026) · Journal of Clinical Medicine · doi:10.3390/jcm15103979
“In the context of anti-EGFR therapy, HER2 amplification or overexpression provides an alternative signaling pathway that bypasses EGFR blockade, thereby conferring resistance [25–28].”
Mulholland, T., Aybey, B., Li, Z., Schwarzmüller, L. E., Rindtorff, N., Tondo, L., Sui, P., Karabati, E., Albrecht, P., Riedesser, J. E., et al. (2026) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2026.07.03.735750
“Factor 1 showed a high association with RAS mutation status and EGFR inhibitor resistance, which is an extensively studied drug-genotype association [16] (Supp.”
Steup, C., Mondorf, A. W., Wild, P. J., Pession, U., Bechstein, W. O., Michael, F. A., Winter, M., Bein, J., Zeuzem, S., Trojan, J., et al. (2026) · PLoS ONE · doi:10.1371/journal.pone.0351243
Beyond Acute EGFR Blockade: Biological Basis and Clinical Evidence for Long-Term Nimotuzumab Therapy
Ramos, T. C., Díaz-Miqueli, A., & Rodríguez, R. P. (2026) · Biomedicines · doi:10.3390/biomedicines14071570
“…extracellular domain (ECD) [59–61]; the compensatory activation of alternative receptor tyrosine kinases, particularly HER2, HER3 and MET [62,63]; and oncogenic mutations in the downstream pathway, including KRAS, NRAS, BRAF, and PIK3CA, that enable ligand-independent proliferation [64–66]…”
Lupo, B., Catalano, I., & Trusolino, L. (2026) · Molecular Cancer · doi:10.1186/s12943-026-02747-x
“These limitations stem not only from interpatient genomic heterogeneity [20–22], but also from the dynamic and adaptive nature of tumor biology.”
Self-citationGanguly, D., GHOSH, S., Deka, H., Sarmah, J., Majumdar, S., Mahanti, K., Hoque, N., & Ghosh, S. (2026) · Clinical & Translational Oncology · doi:10.1007/s12094-026-04516-0
Kim, S. Y., & You, M. (2026) · Cell Death Discovery · doi:10.1038/s41420-026-03293-7
KRAS、BRAF変異大腸癌細胞に対するAURKA阻害薬とMEK阻害薬の併用による相乗的抗腫瘍効果の検討
Masashi, S., 昌志, 佐., & マサシ, サ. (2026) · Institutional Repositories DataBase (IRDB) · doi:10.15068/0002022930
Sadanandam, A., O’Farrell, A. C., Miller, I. S., Hari, P. S., Lärkeryd, A., Venken, T., Arijs, I., Zanella, E. R., Cottino, F., Pinnelli, M., et al. (2026) · Cancer Cell · doi:10.1016/j.ccell.2026.09.014 · Cited by 1
Self-citationTumour assembloids recapitulate tumour–CAF–T cell crosstalk in renal cancer
Kim, E., 강민용, Han, J. H., Lee, J.-H., Kim, Y., Jeong, C. W., Lee, H., Kim, H. J., & Shin, K. (2026) · Nature · doi:10.1038/s41586-026-11208-w
Metadata
- Authors
- Bertotti, A., Papp, E., Jones, S., Adleff, V., Anagnostou, V., Lupo, B., Sausen, M., Phallen, J., Hruban, C. A., Tokheim, C., Niknafs, N., Nesselbush, M., Lytle, K., Sassi, F., Cottino, F., Migliardi, G., Zanella, E. R., Ribero, D., Russolillo, N., Mellano, A., Muratore, A., Paraluppi, G., Salizzoni, M., Marsoni, S., Kragh, M., Lantto, J., Cassingena, A., Li, Q. K., Karchin, R., Scharpf, R., Sartore-Bianchi, A., Siena, S., Diaz, L. A., Trusolino, L., & Velculescu, V. E.
- Affiliations
- Istituto Nazionale Biostrutture e Biosistemi (IT)
- Johns Hopkins University (US)
- Candiolo Cancer Institute (IT)
- Azienda Ospedaliero Universitaria San Giovanni Battista (IT)
- Symphogen (Denmark) (DK)
- Azienda Socio Sanitaria Territoriale Grande Ospedale Metropolitano Niguarda (IT)
- University of Milan (IT)
- Corresponding author
- Bertotti, Andrea
- Trusolino, Livio
- Velculescu, Victor E.
- ORCID
- Bertotti, Andrea
- Papp, Eniko
- Jones, Siân
- Adleff, Vilmos
- Anagnostou, Valsamo
- Lupo, Barbara
- Sausen, Mark
- Phallen, Jillian
- Hruban, Carolyn A.
- Tokheim, Collin
- Niknafs, Noushin
- Nesselbush, Monica
- Sassi, Francesco
- Cottino, Francesca
- Migliardi, Giorgia
- Zanella, Eugenia R.
- Ribero, Dario
- Russolillo, Nadia
- Mellano, Alfredo
- Muratore, Andrea
- Salizzoni, Mauro
- Marsoni, Silvia
- Kragh, Michael
- Lantto, Johan
- Cassingena, Andrea
- Li, Qing Kay
- Karchin, Rachel
- Scharpf, Robert
- Siena, Salvatore
- Diaz, Luis A.
- Trusolino, Livio
- Velculescu, Victor E.
- Venue
- Nature
- Published
- 2015-09-30
- Volume
- 526
- Issue
- 7572
- Pages
- 263-267
- ISSN
- 0028-0836 (ISSN-L)
- 1476-4687
- PMC
- PMC4878148
- OpenAlex
- W2102354469
- Cited by
- 479
- References
- 41
- Citations by year
- 2026: 16 · 2025: 28 · 2024: 37 · 2023: 35 · 2022: 47 · 2021: 50 · 2020: 47 · 2019: 59 · 2018: 56 · 2017: 57 · 2016: 43 · 2015: 3
- FWCI
- 23.15
- Type
- journal article
- Language
- en
- Update notices
- correction (2026-02-16)
- Open access
- green
- www.ncbi.nlm.nih.gov
- Licence
- www.springernature.com/gp/researchers/text-and-data-mining (tdm)
- www.springernature.com/gp/researchers/text-and-data-mining (vor)
- Locations
- Nature (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- Institutional Research Information System University of Turin (University of Turin) (submittedVersion, other-oa)
- RePEc: Research Papers in Economics (submittedVersion)
- Funders
- National Institutes of Health (5r01ca121113-15)
- National Cancer Institute (R01-CA121113, CA-121113, P30CA006973)
- National Institute of General Medical Sciences (T32GM007057)
- Topics
- Health Sciences › Medicine › Oncology › Colorectal Cancer Treatments and Studies
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Treatments and Mutations
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer Genomics and Diagnostics
- Keywords
- EGFR inhibition, anti-EGFR antibody therapy, cetuximab, panitumumab, treatment resistance, primary resistance, somatic mutations, ERBB2, FGFR1, PDGFRA, MEK1, KRAS wild-type
- MeSH terms
- Cetuximab, Panitumumab, Animals, Antibodies, Monoclonal, Antineoplastic Agents, Female, Humans, Mutation, Colorectal Neoplasms, Genome, Human, Proto-Oncogene Proteins p21(ras), Receptor, ErbB-2, Erb-b2 Receptor Tyrosine Kinases, Drug Resistance, Neoplasm, Receptor, Platelet-Derived Growth Factor alpha, Xenograft Model Antitumor Assays, Genomics, MAP Kinase Kinase 1, Mice, Receptor, Fibroblast Growth Factor, Type 1, Insulin Receptor Substrate Proteins, DNA Copy Number Variations, Molecular Targeted Therapy, Exome, ErbB Receptors
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.